CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.
  
  LEARNING OBJECTIVES

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, head and neck, gastrointestinal, genitourinary, dermatologic, gynecologic and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, lung, head and neck, gastrointestinal, genitourinary, dermatologic, gynecologic and select hematologic cancers, and refer appropriate patients for study participation.
  • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  

  Jeremy Abramson, MD
  Director, Center for Lymphoma
  Massachusetts General Hospital
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts

  Consulting Agreements: AbbVie Inc, Allogene Therapeutics, Celgene Corporation, EMD Serono Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Karyopharm Therapeutics, Kite Pharma Inc, MorphoSys, Novartis, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Seattle Genetics.

  Tanios Bekaii-Saab, MD
  Professor, Mayo Clinic College of Medicine and Science
  Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center
  Vice-Chair and Section Lead, Division of Medical Oncology
  Medical Director, Cancer Clinical Research Office
  Senior Associate Consultant
  Mayo Clinic
  Phoenix, Arizona

  Advisory Committee: Amgen Inc, Immuneering Corporation, Imugene; Consulting Agreements: AbbVie Inc, Array BioPharma Inc, Bayer HealthCare Pharmaceuticals; Contracted Research: Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Astellas, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Ipsen Biopharmaceuticals Inc, Novartis; Data and Safety Monitoring Board/Committee: ARMO BioSciences, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Merck, SillaJen.

  Johanna Bendell, MD
  Chief Development Officer
  Director, Drug Development Unit Nashville
  Sarah Cannon Research Institute
  Tennessee Oncology
  Nashville, Tennessee

  Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna Inc, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Prelude Therapeutics, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Tolero Pharmaceuticals, Torque Therapeutics, Translational Drug Development; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Nektar, Novartis, Novocure, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Rgenix, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Shattuck Labs, Sierra Oncology, SynDevRx Inc, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Unum Therapeutics, Vyriad; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc.

  Michael J Birrer, MD, PhD
  Director, Winthrop P Rockefeller Cancer Institute
  Director, Cancer Service Line
  University of Arkansas
  Little Rock, Arkansas

  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company.

  Hossein Borghaei, MS, DO
  Professor and Chief, Thoracic Oncology
  The Gloria and Edmund M Dunn Chair in Thoracic Oncology
  Fox Chase Cancer Center
  Philadelphia, Pennsylvania

  Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Genmab, Lilly, Merck, Novartis, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Axiom Life Sciences Group LLC, Bristol-Myers Squibb Company, HUYA Bioscience International, Lilly, Merck; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck, Takeda Oncology; Data and Safety Monitoring Board/Committee: Incyte Corporation, Takeda Oncology, University of Pennsylvania, Vanderbilt University; Scientific Advisory Board: Rgenix, Sonnet BioTherapeutics.

  Harold J Burstein, MD, PhD
  Professor of Medicine
  Harvard Medical School
  Breast Oncology Center
  Dana-Farber Cancer Institute
  Boston, Massachusetts

  No financial interests or affiliations to disclose.

  Barbara Burtness, MD
  Professor of Medicine
  Yale School of Medicine
  Co-Leader, Developmental Therapeutics Program
  Yale Cancer Center
  New Haven, Connecticut

  Advisory Committee: Aduro Biotech, ALX Oncology, Celgene Corporation, Cue Biopharma, Merck, Nanobiotix, Oncolys BioPharma, Rakuten Medical; Consulting Agreement: Celgene Corporation; Contracted Research: Aduro Biotech, Bristol-Myers Squibb Company, Celldex Therapeutics, Forbius, Merck; Data and Safety Monitoring Board/Committee: IDDI, Kura Oncology.

  Matthew S Davids, MD, MMSc
  Assistant Professor of Medicine, Harvard Medical School
  Director, DFCI Lymphoma BioBank
  Associate Director, CLL Center
  Dana-Farber Cancer Institute
  Boston, Massachusetts

  Advisory Committee: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, BeiGene, Genentech, a member of the Roche Group, Janssen Biotech Inc, MEI Pharma Inc, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, Verastem Inc; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc.

  Robert Dreicer, MD, MS
  Section Head, Medical Oncology
  Deputy Director, University of Virginia Cancer Center
  Associate Director for Clinical Research
  Professor of Medicine and Urology
  University of Virginia School of Medicine
  Charlottesville, Virginia

  Advisory Committee: Astellas, Eisai Inc, Janssen Biotech Inc, Novartis, Orion Corporation, Pfizer Inc, Seattle Genetics, Vizuri Health Sciences; Contracted Research: Bristol-Myers Squibb Company, Exelixis Inc, Pfizer Inc, Seattle Genetics.

  Jonathan W Friedberg, MD, MMSc
  Samuel E Durand Professor of Medicine
  Director, James P Wilmot Cancer Institute
  University of Rochester
  Rochester, New York

  Data and Safety Monitoring Board/Committee: Acerta Pharma — A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals.

  Charles E Geyer Jr, MD
  Deputy Director
  Houston Methodist Cancer Center
  Houston, Texas

  Advisory Committee (Uncompensated): Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Genentech, a member of the Roche Group, Roche Laboratories Inc; Paid Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Roche Laboratories Inc; Writing Assistance: AbbVie Inc, Genentech, a member of the Roche Group, Roche Laboratories Inc.

  Erika Hamilton, MD
  Director, Breast and Gynecologic Research Program
  Sarah Cannon Research Institute
  Nashville, Tennessee

  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Lilly, Mersana Therapeutics, NanoString Technologies, Novartis, Pfizer Inc, Puma Biotechnology Inc, Silverback Therapeutics; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Aravive Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, BerGenBio ASA, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Fochon Pharmaceuticals Ltd, Fosun Orinove PharmaTech Inc, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, Immunomedics Inc, InventisBio, Karyopharm Therapeutics, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Medivation Inc, a Pfizer Company, Mersana Therapeutics, Merus BV, Molecular Templates, Novartis, NuCana, OncoMed Pharmaceuticals Inc, Pfizer Inc, Puma Biotechnology Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Rgenix, Seattle Genetics, Sermonix Pharmaceuticals, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Torque Therapeutics, Unum Therapeutics, Verastem Inc, Zenith Epigenetics Ltd, Zymeworks.

  Leora Horn, MD, MSc
  Ingram Associate Professor of Cancer Research
  Director, Thoracic Oncology Research Program
  Assistant Vice Chairman for Faculty Development
  Vanderbilt University Medical Center
  Nashville, Tennessee

  Advisory Committee: EMD Serono Inc, Genentech, a member of the Roche Group, Xcovery; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, Pfizer Inc, Roche Laboratories Inc, Tesaro, A GSK Company, Xcovery; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Merck, Takeda Oncology, Xcovery; Paid Travel: Bristol-Myers Squibb Company, Xcovery.

  Virginia Kaklamani, MD, DSc
  Professor of Medicine
  Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
  AB Alexander Distinguished Chair in Oncology
  Associate Director for Clinical Research
  Leader of the Breast Cancer Program
  UT Health San Antonio
  The University of Texas MD Anderson Cancer Center
  San Antonio, Texas

  Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Athenex, Celldex Therapeutics, Eisai Inc, Puma Biotechnology Inc; Contracted Research: Eisai Inc; Speakers Bureau: Celgene Corporation, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc.

  Stephen V Liu, MD, PhD
  Associate Professor of Medicine
  Georgetown University Hospital
  Washington, DC

  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, G1 Therapeutics, Genentech, a member of the Roche Group, Guardant Health, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, PharmaMar, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Merck Sharp & Dohme Corp, Pfizer Inc, Takeda Oncology; Contracted Research: Alkermes, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Genentech, a member of the Roche Group, Lilly, Lycera, Merck, Merus BV, Molecular Partners, Pfizer Inc, Rain Therapeutics, RAPT Therapeutics, Spectrum Pharmaceuticals Inc, Turning Point Therapeutics; Data and Safety Monitoring Board/Committee: Taiho Oncology Inc.

  Sagar Lonial, MD
  Chair and Professor
  Department of Hematology and Medical Oncology
  Chief Medical Officer
  Winship Cancer Institute
  Emory University
  Atlanta, Georgia

  Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.

  Jason J Luke, MD
  Associate Professor and Director of the Cancer Immunotherapeutics Center
  University of Pittsburgh Medical Center and
  Hillman Cancer Center
  Pittsburgh, Pennsylvania

  Advisory Committee: 7 Hills Pharma LLC, AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Pyxis Oncology, Spring Bank Pharmaceuticals Inc, Tempest Therapeutics Inc; Consulting Agreements: AbbVie Inc, Akrevia Therapeutics, Aligos Therapeutics, Array BioPharma Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, IDEAYA Biosciences, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, RefleXion, Silicon Therapeutics, Tesaro, A GSK Company, Vividion Therapeutics; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Checkmate Pharmaceuticals, Compugen Inc, Corvus Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, Genentech, a member of the Roche Group, Immatics Biotechnologies GmbH, Immunocore , Incyte Corporation, Leap Therapeutics Inc, MacroGenics Inc, Merck, Nektar, Novartis, Palleon Pharmaceuticals, RAPT Therapeutics, Spring Bank Pharmaceuticals Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc, Xencor; Data and Safety Monitoring Board/Committee: TTC Oncology; Paid Travel: Akrevia Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, Pyxis Oncology, RefleXion; Ownership Interest: AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Pyxis Oncology, Tempest Therapeutics Inc.

  John L Marshall, MD
  Chief, Hematology and Oncology
  Director, Ruesch Center for the Cure of GI Cancers
  Lombardi Comprehensive Cancer Center
  Georgetown University
  Washington, DC

  Advisory Committee, Consulting Agreements and Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Celgene Corporation, Indivumed GmbH, Roche Laboratories Inc, Taiho Oncology Inc; Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Merck, Roche Laboratories Inc, Taiho Oncology Inc.

  Anthony R Mato, MD, MSCE
  Associate Attending
  Director, Chronic Lymphocytic Leukemia Program
  Memorial Sloan Kettering Cancer Center
  New York, New York

  Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Octapharma, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc; Contracted Research: Celgene Corporation, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Board/Committee: Celgene Corporation, TG Therapeutics Inc.

  Wells A Messersmith, MD
  Professor and Head, Division of Medical Oncology
  Associate Director for Translational Research
  University of Colorado Cancer Center
  Aurora, Colorado

  Contracted Research: Aduro Biotech, ALX Oncology, AstraZeneca Pharmaceuticals LP, BeiGene, D3 Pharma, Gossamer Bio, Immunomedics Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc, QED Therapeutics.

  Kathleen Moore, MD
  The Virginia Kerley Cade Endowed Chair in Cancer Development
  Associate Director, Clinical Research
  Director, Oklahoma TSET Phase I Program
  Stephenson Cancer Center
  Associate Professor, Section of Gynecologic Oncology
  Director, Gynecologic Oncology Fellowship
  Department of Obstetrics and Gynecology
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma

  Advisory Committee: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Merck, Mereo BioPharma, Tarveda Therapeutics, Tesaro, A GSK Company, Vavotar Life Sciences; Contracted Research: Clovis Oncology, Genentech, a member of the Roche Group, Merck, PTC Therapeutics; Employment: GOG Foundation/Partners.

  William K Oh, MD
  Chief, Division of Hematology and Medical Oncology
  Professor of Medicine and Urology
  Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
  Icahn School of Medicine at Mount Sinai
  Associate Director of Clinical Research
  The Tisch Cancer Institute
  Mount Sinai Health System
  New York, New York

  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CPS Companion Diagnostics, Janssen Biotech Inc, Sanofi Genzyme, Sema4, TeneoBio.

  Alexander Perl, MD
  Associate Professor of Medicine
  Perelman School of Medicine at the University of Pennsylvania
  Member, Leukemia Program
  Abramson Cancer Center of the University of Pennsylvania
  Philadelphia, Pennsylvania

  Advisory Committee: AbbVie Inc, Actinium Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc, FORMA Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, NewLink Genetics; Consulting Agreements: AbbVie Inc, Arog Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc; Contracted Research: AbbVie Inc, Astellas, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Leukemia & Lymphoma Society.

  Daniel P Petrylak, MD
  Professor of Internal Medicine (Medical Oncology) and Urology
  Yale University
  New Haven, Connecticut

  Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Endocyte Inc, Genentech, a member of the Roche Group, Innocrin Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Inc.

  Paul G Richardson, MD
  Clinical Program Leader
  Director of Clinical Research
  Jerome Lipper Multiple Myeloma Center
  Department of Medical Oncology
  Dana-Farber Cancer Institute
  RJ Corman Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts

  Advisory Committee: Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Oncopeptides, Takeda Oncology.

  Gregory J Riely, MD, PhD
  Associate Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York

  Contracted Research: Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.

  Kerry Rogers, MD
  Assistant Professor in the Division of Hematology
  The Ohio State University
  Columbus, Ohio

  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Genentech,  a member of the Roche Group, Janssen Biotech Inc; Paid Travel: AstraZeneca Pharmaceuticals LP.

  Tanguy Y Seiwert, MD
  Director, Head and Neck Cancer Oncology Disease Group
  Co-Director, Bloomberg-Kimmel Institute for Immunotherapy — HNC Program
  Assistant Professor of Oncology and Otolaryngology
  Johns Hopkins University
  Baltimore, Maryland

  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cue Biopharma, Innate Pharma, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Maverick Therapeutics, Merck, Merck Sharp & Dohme Corp, Nanobiotix, Roche Diagnostics; Ownership Interest: SQZ Biotech.

  Matthew R Smith, MD, PhD
  Claire and John Bertucci Endowed Chair in Genitourinary Cancers
  Professor of Medicine
  Harvard Medical School
  Director, Genitourinary Malignancies Program
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts

  Advisory Committee and Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Janssen Biotech Inc, Lilly.

  Mitchell R Smith, MD, PhD
  Professor of Medicine
  Associate Center Director for Clinical Investigations
  Director, Division of Hematology and Oncology
  GW Cancer Center
  Washington, DC

  Data and Safety Monitoring Board/Committee: Eastern Cooperative Oncology Group; Speakers Bureau: AstraZeneca Pharmaceuticals LP, EUSA Pharma.

  Sonali M Smith, MD
  Elwood V Jensen Professor of Medicine
  Interim Chief, Section of Hematology/Oncology
  Director, Lymphoma Program
  The University of Chicago
  Chicago, Illinois

  Consulting Agreements: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, a member of the Roche Group, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Curis Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Novartis, Portola Pharmaceuticals Inc, Seattle Genetics, TG Therapeutics Inc; Honorarium: Genentech, a member of the Roche Group.

  Eytan M Stein, MD
  Assistant Attending Physician
  Director, Center for Drug Development in Leukemia
  Leukemia Service, Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York

  Advisory Committee: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Menarini Group, Novartis, PTC Therapeutics, Seattle Genetics, Syros Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Syros Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Cellectis, Epizyme; Ownership Interest: Auron Therapeutics.

  Jeffrey S Weber, MD, PhD
  Deputy Director
  Laura and Isaac Perlmutter Cancer Center
  Professor of Medicine
  NYU Langone Medical Center
  New York, New York

  Consulting Agreements: Altor Bioscience Corp, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Biond Biologics, Blueprint Medicines, Bristol-Myers Squibb Company, Celldex Therapeutics, CytomX Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, Merck, Pfizer Inc, Protean LLC, Sellas Life Sciences, Takeda Oncology; Contracted Research: NextCure; Data and Safety Monitoring Board/Committee: Pfizer Inc; Ownership Interest: Altor Bioscience Corp, Biond Biologics, CytomX Therapeutics, Protean LLC; Other: Named on a patent for a PD-1 biomarker by Biodesix Inc, and for a CTLA-4 biomarker by Moffitt Cancer Center.

  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

  This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Array BioPharma Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Lilly, Merck, Novartis, Oncopeptides, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, administered by Janssen Scientific Affairs LLC, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, and Taiho Oncology Inc.

  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: April 2020
  Expiration date: April 2021